Expression of prostacyclin-stimulating factor (PSF) in mononuclear cells of human peripheral blood and THP-1 derived macrophage-like cells, and effects of high glucose concentration by Etoh, Takashi et al.
EXCLI Journal 2005;4:141-151 – ISSN 1611-2156 
Received: 5. October 2005, accepted: 13. December 2005, published: 20. December 2005 
 
Original article: 
 
Expression of prostacyclin-stimulating factor (PSF) in mononuclear cells of 
human peripheral blood and THP-1 derived macrophage-like cells, and 
effects of high glucose concentration 
 
Takashi Etoh1, *, Toshihiko Hashimoto2, Naotaka Sekiguchi3, Minako Imamura3, Toyoshi 
Inoguchi3, Hajime Nawata3
 
1Medical Co. LTA, Medical Co. LTA (PS Clinic), 6-18 Tenya-machi, Hakata-ku, Fukuoka-
city, Fukuoka, 812-0025, Japan, Tel: +81 92 283 7777, Fax: +81 92 283 7770, E.mail: 
takashi-eto@lta-med.com (*corresponding author), 2Fukuoka City Hospital, Fukuoka, Japan, 
3Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, 
Kyushu University, Fukuoka, Japan 
 
 
ABSTRACT 
Prostacyclin (PGI2) synthesis by vascular endothelial cells (ECs) decreases in diabetic 
subjects, possibly leading to development of diabetic angiopathies including that in 
atherosclerosis. We identified a bioactive peptide, prostacyclin-stimulating factor (PSF), 
which stimulates PGI2 synthesis in cultured aortic ECs. Our previous studies demonstrated 
that PSF was predominantly expressed by arterial smooth muscle cells (SMCs) and ECs. We 
immunohistochemically showed that PSF existed in SMCs of human coronary arteries, and 
PSF staining was markedly reduced in coronary arterial SMCs of patients with type 2 diabetes 
and/or myocardial infarction. In the present study, we investigated the existence of PSF in 
human serum, and effects of glucose on serum PSF levels in patients with type 2 diabetes. 
Immunoblot analysis revealed the presence of PSF in serum, and showed that serum PSF 
protein concentration was significantly decreased in type 2 diabetic patients. Moreover, there 
was a significant negative correlation between serum PSF and HbA1c levels in these patients. 
Using immunohistochemistry, we also showed that PSF was present in serum and in 
macrophages (Mφs). PSF mRNA was found in Mφs using reverse transcription-polymerase 
chain reaction (RT-PCR). In addition, effects of high glucose conditions on PSF production in 
Mφs were examined by Western blotting, and we showed that PSF significantly decreased 
when Mφs were cultured in high glucose conditions. These results strongly suggested that 
decreased PSF production might result in decreased production of PGI2 in atherosclerotic 
lesions, thus leading to development of diabetic macroangiopathy and atherosclerosis. 
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INTRODUCTION 
 
Prostacyclin (PGI2) is mainly synthesized by 
vascular endothelial cells (ECs). It is a potent 
vasodilator, and inhibitor of platelet adhesion 
and aggregation, and also contributes to the 
maintenance of vessel wall homeostasis 
(Moncada et al., 1976; Moncada, 1982). It 
has been previously reported that vascular 
PGI2 synthesis was reduced in patients with 
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diabetes (Colwell et al., 1983; Inoguchi et al., 
1987) and atherosclerosis (Larrue, 1980). 
Decreased PGI2 production could be 
associated with pathogenesis of vascular 
lesions such as those seen in diabetic 
angiopathy and atherosclerosis. In addition to 
results described by Maclntyre et al. (1978), 
we demonstrated that human serum 
stimulated PGI2 production in cultured 
bovine aortic ECs (Inoguchi et al., 1987), and 
that activity of serum stimulating PGI2 
production decreased in patients with 
diabetes as well as in an animal model of 
diabetes (Inoguchi et al., 1986; Inoguchi et 
al., 1992). 
 
Moreover, we found that cultured bovine 
aortic ECs similarly stimulated PGI2 
production in serum-free conditioned 
medium from cultured human fibroblast cells 
(Yamauchi et al., 1993). We also purified 
and cloned a novel bioactive peptide, 
prostacyclin-stimulating factor (PSF), which 
was responsible for stimulation of PGI2 
production (Yamauchi et al., 1994). PSF 
mRNA is particularly expressed in lungs and 
kidneys of humans and rats (Ono et al., 
1994). 
 
In vitro, PSF production by ECs and SMCs 
was reduced when these cells were cultured 
in high glucose conditions. 
 
Decreased PSF production leads to 
decreasing PGI2 concentration, and to vessel 
wall constriction, followed by platelet 
aggregation. In local lesions of vessel walls, 
ECs, SMCs, and Mφs play important roles, 
because Mφs synthesize tumor necrosis 
factor-α( TNF-α) , endothelin-I (ET-I), and 
other factors associated with pathogenesis of 
atherosclerosis. 
 
In the present study, we investigated whether 
activated mononuclear cells produced PSF. 
We also examined effects of high glucose 
concentrations on PSF production in 
macrophage-like cells derived from the THP-
1 cell line that was purified from human 
acute monocytic leukemia. 
MATERIALS AND METHODS  
 
Experimental subjects and treatment of blood 
samples 
Following an overnight fast, whole blood 
was randomly collected from 14 patients 
with type 2 diabetes (male/female, 4/10; 
mean age, 59 years old), and from 10 age-
matched healthy controls (male/female, 5/5; 
mean age, 58 years old). Serum was 
immediately separated, and applied to a 
heparin affinity column (HiTrap Heparin, 
Pharmacia Biotech, Japan) which had been 
equilibrated with two column volumes of 
0.01 M sodium phosphate buffer (start 
buffer) at pH 7.0. After washing with the 
start buffer until the effluent was clear, the 
heparin-bound fraction containing PSF 
proteins was eluted with two column 
volumes of start buffer and 1 mM Tris-HCl 
at 4 oC. Measurement of protein 
concentration and western blot analysis are 
described as follows. 
 
Measurement of glycocylated hemoglobin 
A1c 
Glycocylated hemoglobin A1c (HbA1c) was 
measured by high-performance liquid 
chromatography (HPLC). 
 
Isolation of human mononuclear cells from 
cultured THP-1 cells and peripheral blood 
The THP-1 cell line was purified from 
human acute monocytic leukemia, and was 
cultured in RPMI-1640 medium (Gibco 
Laboratories, NY) containing 5 % fetal 
bovine serum (FBS, Gibco), 5.5 mM glucose 
(Sigma-Aldrich, Japan), 100 µU/ml 
penicillin, and 50 µg/ml streptomycin 
(Gibco), under 95 % air and 5 % CO2 at 37 
oC. Cells were stimulated to transform to 
macrophage-like cells by addition of phorbol 
12-myristoyl 13-acetate (PMA, Sigma-
Aldrich) into the culture medium of an initial 
density of 1 × 106 cells/ml, followed by 48-h 
culture period (with 0.1 µM PMA). Then, 
cells were washed with phosphate-buffered 
saline (PBS, Sigma-Aldrich), cultured with 
5.5 mM glucose for 72 h, and incubated with 
different concentrations of glucose for 72 h. 
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Human mononuclear cells were isolated from 
buffy coat preparations of whole blood taken 
from healthy volunteers. In brief, each buffy 
coat was mixed with Lymphocyte Separation 
Medium (ICN/Cappel R.O.) and 
physiological saline in a ratio of 3:2:2, and 
centrifuged for 30 min at 400 x g at room 
temperature. Then, the supernatant was 
removed, and the cell layer was transferred to 
a new tube. PBS (vol) was added, and the 
pellet was centrifuged for 10 min at 250 x g 
at 4 oC. The supernatant was removed, and 
resuspended in RPMI 1640 supplemented 
with 10 % FBS. For monocyte-macrophage 
differentiation, monocytes isolated as above 
were resuspended in culture medium at a 
density of 3 × 106/ml, seeded into 100-mm2 
tissue culture dishes (NUNC Denmark), 
incubated for 2 h at 37 oC, and washed four 
times with culture medium. Isolated cells 
were incubated at 37 oC for 7 days, and 
medium was changed every 48 h. 
 
Reverse transcription-polymerase chain 
reaction (RT-PCR) of mononuclear cells and 
THP-1 derived macrophage-like cells 
Total RNAs of human mononuclear cells and 
macrophage-like cells were isolated with 
ISOGEN (Nippon gene, Japan). Single-
stranded cDNAs were prepared from total 
RNAs using random primers and Superscript 
II (Gibco BRL), by incubating for 60 min at 
42 oC. Resulting single-stranded cDNAs 
were amplified using specific primers (Table 
1) and the KOD plus polymerase (TOYOBO, 
Japan). PCR conditions involved 30 cycles of 
1 min at 94 oC, 1 min at 50 oC, and 1 min at 
72 oC. PCR products were purified with 
QIAquick PCR Purification Kit (QIAGEN, 
C.A.). Following purification of PCR 
products, DNA sequences were determined. 
 
 
 
Table 1: Primer sequences for RT-PCR 
 
PSF 
 Sense, 5’-CATGGAGTGCGTGAAGAGCCGC-3’ 
 Antisense, 5’-GAATTGGATGCATGGCACTCATATTC-3’ 
 
B-actin 
 Sense, 5’-AGAGATGGCCACGGCTGCTT-3’ 
 Antisense, 5’-ATTTGCGGTGGACGATGGAG-3’ 
 
 
Immunohistochemistry 
Monoclonal antibodies against PSF were 
generated from mice as described previously 
(Hata et al., 2000). Immunohistochemistry 
was performed using the avidin-biotin 
peroxidase complex method. Macrophage-
like cells were fixed on slide glasses by the 
method of cytospin, centrifuged at 3,000 rpm 
for 5 min at room temperature. Slides were 
incubated with 0.2 % Triton X-100 (Sigma-
Aldrich) for 2 min at room temperature, and 
blocked with 3 % H2O2 (Sigma-Aldrich) in 
methanol to eliminate endogeneous 
peroxidase for 30 min on ice. Then, slides 
were incubated with 10 % normal goat serum 
(Amersham Pharmacia Biotech, UK) for 60 
min at room temperature to block nonspecific 
bindings, followed by incubation with anti-
PSF monoclonal antibody (5 µg/ml) 
overnight at 4 oC. Control specimens of 
macrophage-like cells (negative control) 
were incubated with PBS and normal mouse 
IgG (5 µg/ml, Amersham Pharmacia 
Biotech). After washing with PBS, the 
specimens were further incubated with 
biotinylated goat anti-mouse IgGs (1:2,000, 
Amersham Pharmacia Biotech) for 30 min, 
followed by incubation with a solution of 
avidin-biotin peroxidase complex (Histofine 
System, Nichirei, Japan), for 30 min at room 
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temperature. Finally, a diaminobenzidine 
solution (DAB, Nichirei) was applied to 
visualize immunoreaction for PSF, and 
nuclei of the specimens were counterstained 
with hematoxylin. 
 
Western blot analysis of blood samples and 
culture medium 
Blood samples were separated as described 
previously. After incubation with different 
concentrations of glucose for 72 h, culture 
medium was dialyzed with dialysis buffer (5 
mM Tris-HCl (Sigma-Aldrich), pH 7.4) for 
48 h at 4 oC, and dialysis buffer was changed 
at 24 h. The dialyzed culture medium was 
treated with a SpeedVac Concentrator SVC 
100H (SAVANT) in an attempt to increase 
its concentration. Protein concentration was 
determined using the BCA Protein Assay Kit. 
Thirty-five µg proteins of each sample were 
mixed with loading buffer (10 mM Tris-HCl, 
pH 6.8, 1 % sodium dodecyl sulfate (SDS 
(Sigma-Aldrich)), 20 % glycerol (Sigma-
Aldrich), 0.02 % bromophenol blue (Sigma-
Aldrich), 1 % 2-mercaptoethanol (Sigma-
Aldrich)), and boiled for 2 min. Samples 
were separated using 12 % SDS/PAGE with 
a running buffer  including 25 mM Tris, 192 
mM glycine (Sigma-Aldrich), and 0.1 % 
SDS. Proteins were then electrophoretically 
transferred to a nitrocellulose membrane 
(Hybond-C super, Amersham LIFE 
SCIENCE) at 1 mA/cm2 of paper for 90 min 
using transfer buffer (20 % vol/vol methanol 
(Sigma-Aldrich), 25 mM Tris, 192 mM 
glycine, 0.05 % SDS). The membrane was 
incubated in T-PBS buffer (100 mM 
phosphate buffer containing 100 mM NaCl 
(Sigma-Aldrich), 0.1 % Tween-20 (Sigma-
Aldrich), 5 % (wt/vol) non fat milk powder) 
for 1 h at room temperature, and with 
monoclonal anti-PSF antibody overnight at 4 
oC. PBS and anti-PSF antibody incubated 
with C-terminal PSF peptides (20 amino 
acids, concentration ratio = 1:5) were used as 
negative control. Then, the membrane was 
washed three times with T-PBS buffer, and 
incubated with horseradish peroxidase-
labeled antibody against mouse IgGs 
(Amersham) for 45 min. Finally, the 
membrane was washed five times with T-
PBS buffer, and the specific band 
corresponding to PSF was visualized by 
enhanced chemiluminescence (ECL plus 
system, Amersham). 
 
Statistical analysis 
Data were expressed as means ± SE. 
Statistical analysis was performed by 
analysis of variance (ANOVA), calculated 
with the Statview program. P values < 0.05 
were considered to be statistically significant. 
 
 
RESULTS 
Western blot analysis of PSF in serum 
Western blot analysis revealed a PSF band in 
human serum with an approximate molecular 
weight of 31 kDa. We compared density of 
the serum PSF band in type 2 diabetic 
patients with that in age-matched controls. 
Density ratio of the PSF band from each 
experimental subject was expressed relative 
to that of healthy subjects. Density ratio of 
the PSF band representing PSF protein 
concentration in serum, was significantly 
decreased in type 2 diabetic patients 
compared with that in controls (0.69 + 0.03 
vs 1.00 + 0.08, P < 0.01) (Fig.1A). 
 
Correlation between density ratio of the PSF 
band in serum and HbA1c level is shown in 
Fig. 1B. Interestingly, there was a significant 
negative correlation between density ratio of 
the PSF band and HbA1c level in patients 
with type 2 diabetes (r = -0.747, P < 0.01). 
This result indicated that serum PSF 
concentration decreased with deterioration of 
glycemic control in type 2 diabetic patients.
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 A 
 
B 
Figure 1: A. Western blot analysis of PSF contents in serum from type 2 diabetic and 
control subjects. Samples were collected from 14 patients with type 2 diabetes 
(male/female, 4/10; mean age, 59 years old) and from 10 age-matched healthy 
controls (male/female, 5/5; mean age, 58 years old). PSF contents were measured 
by western blot analysis using an anti-PSF monoclonal antibody. Data are expressed 
as means + S. E. M., P < 0.05 vs. healthy controls B. Correlation between density 
ratio of the PSF band and HbA1c level in patients with type 2 diabetes. Glycosylated 
hemoglobin A1c (HbA1c) was measured by high-performance liquid chromatography 
(HPLC). There was a significant negative correlation between density ratio of the 
PSF band and HbA1c level, indicating that serum PSF concentration decreased with 
deterioration of glycemic control (r = -0.747, P < 0.01). 
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Expression of PSF mRNA in cultured 
macrophage-like cells and human 
mononuclear cells 
PSF mRNAs in cultured human mononuclear 
cells derived from peripheral blood and in 
macrophage-like cells derived from the THP-
1 cell line were amplified by RT-PCR. PCR 
products migrated as clear single bands on a 
1 % agarose gel, and molecular size of the 
PSF band was 540 bp, which was in 
accordance with the expected DNA size from 
the human cDNA sequence. PSF mRNA was 
detected in cultured mononuclear cells and in 
macrophage-like cells (Fig. 2). PCR products 
purified using the PCR purification Kit, were 
used for DNA sequencing. The sequences 
obtained matched the human PSF cDNA 
sequence. 
 
 
 
 
Figure 2: PSF mRNA expression in human peripheral mononuclear cells and THP-1 
derived macrophage-like cells. Total RNAs of human mononuclear cells and 
macrophage-like cells were isolated using the ISOGEN method. Single-stranded 
cDNAs were prepared from total RNAs using random primers and Superscript II. The 
resulting single-stranded cDNAs were amplified using specific primers (Table 1) and 
the KOD plus polymerase. PCR products migrated as clear single bands on a 1 % 
agarose gel. Lane 1, PCR product of -actin; Lane 2, PCR product of PSF; Lane 3, 
size marker (Hinc-II). 
 
 
Immunohistochemical study of PSF in 
macrophage-like cells 
Fig. 3 shows immunostaining for PSF in 
macrophage-like cells. Positive 
immunostaining for PSF in macrophage-like 
cells incubated with anti-PSF antibody was 
found, but not in macrophage-like cells 
incubated with PBS and normal mouse IgGs. 
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Figure 3: Immunocytochemical staining in THP-1 derived macrophage-like cells. 
Immunocytochemical staining was performed using the avidin-biotin peroxidase 
complex method. Cultured macrophage-like cells were fixed on slide glasses by the 
method of cytospin. We used anti-PSF monoclonal antibody as primary antibody (5 
µg/ml), and PBS and normal mouse IgGs (5 µg/ml) were used as negative control. 
After washing with PBS, the specimens were further incubated with biotinylated goat 
anti-mouse IgGs as secondary antibody. Finally, a diaminobenzidine solution (DAB) 
was applied to visualize PSF, while cell nuclei of specimens were counterstained with 
hematoxylin. A. Anti-PSF monoclonal antibody, B. PBS, C. Normal mouse IgGs. 
 
Western blot analysis of culture medium 
In addition to immunocytochemical staining, 
we performed Western blot analysis to 
confirm the existence of PSF in cultured 
macrophage-like cells, and to examine 
effects of high glucose on PSF levels in these 
cells. Positive staining for PSF occurred 
when macrophage-like cells were reacted 
with anti-PSF antibody, but not found when 
cells were reacted with normal mouse IgGs 
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or with anti-PSF antibody incubated with 
PSF peptides. The same amount of culture 
medium obtained from macrophage-like cells 
cultured with high glucose concentration 
(500 mg/dl) was examined by 
immunoblotting for PSF, whether there were 
differences in PSF content among cultured 
macrophage-like cells. As shown in Fig. 4, 
western blot analysis indicated that PSF level 
was decreased by 85.4 % (P < 0.05) with 
increasing glucose concentration in the 
culture medium, in parallel to a decrease in 
PSF staining intensity. 
 
 
Figure 4: PSF contents in THP-1 derived macrophage-like cells cultured with normal 
and high concentrations of glucose. THP-1 derived macrophage-like cells were 
cultured with RPMI-1640 medium containing normal or high concentrations of 
glucose for 72 h. Cultured medium was dialyzed with dialysis buffer for 48 h. Thirty-
five µg proteins of each sample were mixed with loading buffer, and samples were 
loaded for 12 % SDS/PAGE. Proteins were then electrophoretically transferred to a 
nitrocellulose membrane. The membrane was incubated with either monoclonal anti-
PSF antibody, or PBS and anti-PSF antibody incubated with C-terminal portions of 
PSF peptides (negative control). Then, the membrane was washed three times with 
T-PBS buffer, and incubated with horseradish peroxidase-labeled antibodies against 
mouse IgGs. Following a final wash with T-PBS buffer, the specific band 
corresponding to PSF was visualized by enhanced chemiluminescence. Data are 
expressed as means + S. E. M. from two different experiments. P < 0.05 vs. normal 
glucose (100 mg/dl), n = 3, respectively 
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DISCUSSION 
Diabetic angiopathy is a well-known 
complication influencing the prognosis of 
diabetes. Many pathogenic factors have been 
shown to promote development of diabetic 
angiopathy. Recently, it has also been 
demonstrated that one of the most important 
causes of diabetic angiopathy are 
dysfunctions of vascular ECs and SMCs, and 
activation of Mφs due to hyperglycemia. ECs 
generate and secrete many vasoactive 
substances regulating vascular tonus such as 
PGI2 (Moncada et al., 1976), endothelium-
derived relaxing factor/nitric oxide 
(Furchgott et al., 1980), and endothelin. Mφs 
also generate and secrete many mediators, 
and are involved in the progression of 
atherosclerosis. 
 
In particular, PGI2 was first discovered by 
Moncada et al. (1976), and was shown to be 
a potent prostanoid acting as a vasodilator 
and an inhibitor of platelet aggregation. A 
decrease in PGI2 production is thought to 
contribute to the pathogenesis of diabetic 
angiopathy (Johnson et al., 1988). 
Circulating PGI2 concentrations are 
decreased in serum from both human and 
animal models with diabetes (Colwell et al., 
1983; Karpen et al., 982), thus resulting in 
platelet hyperfunction, and vascular 
constriction (Udvardy et al., 1987; Ziboh et 
al., 1979; Aanderud et al., 1985; Umeda et 
al., 1989). 
 
Relationships between PGI2 alteration and 
atherosclerotic lesions have also been 
reported (Umeda et al., 1989; Inoguchi et al., 
1991; Sekiguchi et al., 1997). Dembinska-
Kiec et al. (1977) first demonstrated that 
generation of PGI2 by arteries such as the 
coronary artery is reduced in experimentally-
induced atherosclerosis of rabbits that had 
been overfed with cholesterol. Sinzinger et 
al. (1979) also demonstrated that such a 
decreased PGI2 production might injure the 
protective function of vessel walls, and thus 
induce progression of atherosclerosis. It has 
also been reported that PGI2 inhibited 
secretion of cytokines and growth factors by 
Mφs (Willis et al., 1986). Hajjar et al. (1982) 
further demonstrated that PGI2 modulated 
cholesteryl ester hydrolytic activity by 
affecting cAMP synthesis in rabbit aortic 
SMCs. Moreover, Orekhov et al. (1983) 
reported that PGI2 analogs reduced the 
content of intracellular cholesterol in SMCs 
obtained from human atherosclerotic lesions. 
Satya et al. (1989) reported that cholesterol-
rich macrophages decreased synthesis of 
PGI2 and prostaglandin E2 (PGE2). 
Hashimoto et al. (2002) reported that 
lysophosphatidylcholine, which is a main 
component of oxidized low density 
lipoprotein, decreased PSF mRNA 
expression. PSF stimulates PGI2 production, 
therefore low levels of PSF may reduce PGI2 
production. Decreased PSF level may 
initiate, and develop atherosclerotic lesions. 
Such evidence suggests that PGI2 
abnormalities may participate in the 
pathogenesis of atherosclerosis. 
 
We hypothesize that PSF of Mφs is mainly 
secreted, and does not accumulate in the 
cytosol. We also hypothesize that secreted 
PSF is more important than PSF in the 
cytosol, because PSF stimulates PGI2 
production from ECs, which is a protective 
function of vessel walls, and reduces 
progression of atherosclerosis. 
 
We demonstrated that PSF was present in 
human mononuclear cells and THP-1 derived 
macrophage-like cells using RT-PCR, 
immunohistochemistry, and western blotting. 
PSF production by macrophage-like cells 
decreased when cells were cultured with high 
glucose concentrations. We have previously 
demonstrated that high glucose also 
decreased PSF production on ECs and 
SMCs. In the present study, we demonstrated 
that high glucose concentrations decreased 
PSF production on macrophage-like cells. 
We hypothesize that decreased PSF 
production by ECs and SMCs plays an 
important role in atherosclerosis. We also 
believe that PSF production by Mφs is lower 
than that by ECs and SMCs, but decreased 
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PSF production by Mφs also plays a role in 
atherosclerosis. 
 
In conclusion, PSF was found to be produced 
by human peripheral mononuclear cells. PSF 
staining was observed in THP-1 derived 
macrophage-like cells. Furthermore, PSF 
expression was decreased in macrophage-like 
cells cultured in the presence of high glucose 
concentration. These results suggest that 
decreased PSF production may result in 
decreased PGI2 production in vessel walls, 
thus leading to development of diabetic 
macroangiopathy and atherosclerosis. 
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